Compare Super Micro Computer Inc (SMCI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Super Micro Computer Inc trades at $29.99 (market cap $15.41B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.9× Super Micro Computer Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals.
| SMCI | VRTX | |
|---|---|---|
Market Cap | $15.41B | $121.95B |
Sector | Technology | Health |
52-Week High | $60.71 | $529.59 |
52-Week Low | $20.53 | $366.54 |
Enterprise Value | $22.93B | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
